New drugs and vaccines for priority pathogens in antimicrobial resistance – 2019

This call for proposals provides funding for clinical trials to be conducted in sub-Saharan Africa which the aim to develop new or improved medicinal products (drugs and vaccines) or combinations thereof against pathogens on the WHO priority list that also fall within the scope of the EDCTP2 programme, specifically Campylobacter, Salmonella, Streptococcus pneumoniae, and Mycobacterium tuberculosis.

Call identifier: RIA2019AMR

See the corresponding call for proposals

Isoniazid resistance: Resetting the score with boosted ethionamide

TASK Foundation NPC (TASK), Cape Town, South Africa, with partners in France and Spain
Project coordinator: Prof. Andreas Diacon
Starting date: 01 January 20121
Duration: 30 months
EDCTP grant amount: EUR 2,704,719
Grant agreement: RIA2019AMR-2657

A novel pan-TB regimen targeting both host and microbe

The Aurum Institute NPC, Johannesburg, South Africa, with partners in Germany, Mozambique, the Netherlands, South Africa, Tanzania, and the United States of America
Project coordinator: Dr Robert Wallis
Starting date: 01 October 2020
Duration: 60 months
EDCTP grant amount: EUR 8,140,565
Grant agreement: RIA2019AMR-2647

Pediatric phase I/II age de-escalation dose-finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa

Sclavo  Vaccines Association (SVA), Siena, Italy, with partners in Germany, Ghana, Italy, and Switzerland
Project coordinator: Dr Rino Rappuoli
Starting date: 01 March 2021
Duration: 48 months
EDCTP grant amount: EUR 5,698,964
Grant agreement: RIA2019AMR-2658